TET2 mutation does not impact the prognosis of adult acute myeloid leukemia patients receiving a hematopoietic stem cell transplantation in first remission: similar outcome following matched sibling and unrelated versus haploidentical donor transplants in a multi-center retrospective analysis from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

IF 7.9 1区医学 Q1 HEMATOLOGY

Haematologica Pub Date : 2025-06-19 DOI:10.3324/haematol.2025.287326

Lin Li,Yishan Ye,Jacques-Emmanuel Galimard,Myriam Labopin,Depei Wu,Jia Chen,Nicolaus Kröger,Jakob Passweg,Urpu Salmenniemi,Maija Itäla-Remes,Xavier Poiré,Matthias Eder,Johan Maertens,David Burns,Henrik Sengeloev,Gitte Olesen,Didier Blaise,Jürgen Finke,Alain Gadisseur,Ali Bazarbachi,Eolia Brissot,Arnon Nagler,Yi Luo,Jimin Shi,Mohamad Mohty,He Huang,Fabio Ciceri,Norbert Claude Gorin

引用次数: 0

Abstract

Not available.

查看原文本刊更多论文

TET2突变不会影响首次缓解期接受造血干细胞移植的成年急性髓性白血病患者的预后：来自欧洲血液和骨髓移植学会全球委员会和急性白血病工作组的一项多中心回顾性分析显示，匹配的兄弟姐妹和非亲属与单倍体相同供体移植的结果相似。

不可用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Haematologica 医学-血液学

CiteScore

14.10

自引率

2.00%

发文量

349

审稿时长

3-6 weeks

期刊介绍： Haematologica is a journal that publishes articles within the broad field of hematology. It reports on novel findings in basic, clinical, and translational research. Scope: The scope of the journal includes reporting novel research results that: Have a significant impact on understanding normal hematology or the development of hematological diseases. Are likely to bring important changes to the diagnosis or treatment of hematological diseases.